Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized dose-ranging study of PRM-151 in myelofibrosis
MOH_2020-10-06_009383Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zinpentraxin alfa in primary myelofibrosis (PMF) and myelofibrosis (MF) (3 arms), sponsored by Roche. Started Aug 2016; status: completed.
02
Drugs
zinpentraxin alfa
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2020-10-06_009383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-06_009383.